Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval

Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review Board approval for its optimized Phase 2 study of Teverelix in men following a first episode of acute ...

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic ...

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced it has received central ...

Adia Nutrition Announces Three Pivotal Clinical Studies Receive Major IRB Milestone - Final Approval Now Clearly in Sight

In addition, Adia has received the first round of comments from the IRB on its Kidney Study. This randomized, single-blind, three-arm crossover trial is evaluating the safety and preliminary efficacy ...
Enid News & Eagle

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical ...

Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative ...